Identification of an androgen withdrawal responsive phenotype in castrate resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA)

被引：1
|
作者：
Logothetis, C. J.
Wen, S.
Molina, A.
Chieffo, N.
Smith, L. A.
Troncoso, P.
Efstathiou, E.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Cougar Biotechnol, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5017
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tumor responses after steroid switch of prednisolone (P) to dexamethasone (D) in castration-resistant prostate cancer (CRPC) patients (pts) on abiraterone acetate (AA)
    Lorente, D.
    Weatherstone, K.
    Omlin, A.
    Pezaro, C.
    Ferraldeschi, R.
    Parker, C.
    Dearnaley, D.
    Harland, S.
    De Bono, J.
    Attard, G.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
  • [22] Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)
    Pal, Sumanta Kumar
    Patel, Jaymala
    He, Miaoling
    Foulk, Brad
    Kraft, Katherine
    Smirnov, Denis A.
    Twardowski, Przemyslaw
    Kortylewski, Marcin
    Bhargava, Vipul
    Jones, Jeremy O.
    CANCER, 2018, 124 (06) : 1216 - 1224
  • [23] A phase I study of testosterone in patients (pts) with early castrate resistant prostate cancer (CRPC)
    Knight, D. A.
    Mohile, S. G.
    Posadas, E. M.
    Manchen, E. A.
    Stadler, W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Metabolic syndrome and inflammation in castration resistant prostate cancer (CRPC) patients (pts) treated with abiraterone (abi) and enzalutamide (enza)
    Conteduca, V.
    Caffo, O.
    Galli, L.
    Maugeri, A.
    Scarpi, E.
    Maines, F.
    Chiuri, V.
    Lolli, C.
    Kinspergher, S.
    Schepisi, G.
    Santoni, M.
    Santini, D.
    Fratino, L.
    Burgio, S. L.
    Salvi, S.
    Menna, C.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Molina, A. M.
    Christos, P. J.
    Whang, Y.
    Nordquist, L.
    Hackett, A. L.
    Beltran, H.
    Faltas, B.
    Nanus, D.
    Giannakakou, P.
    Tagawa, S. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Androgen receptor (AR) based biomarker association with response to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC).
    Kohli, Manish
    Wang, Liguo
    Sicotte, Hugues
    Qin, Rui
    Carlson, Rachel
    Eckel-Passow, Jeanette
    Tan, Winston
    Wu, Kevin
    Dehm, Scott
    Eiken, Patrick W.
    Jimenez, Rafael E.
    Cernigliaro, Joseph
    Quevedo, Fernando
    Costello, Brian Addis
    Pitot, Henry Clement
    Moynihan, Timothy J.
    Ho, Thai Huu
    Dronca, Roxana Stefania
    Bryce, Alan Haruo
    Wang, Liewei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [27] Molecular profiling of circulating tumor cells (CTC) in patients with castrate resistant prostate cancer (CRPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy
    Danila, Daniel C.
    Anand, Aseem
    Sung, Clifford C.
    Leversha, Margaret
    Cao, Long
    Fleisher, Martin
    Scher, Howard I.
    CANCER RESEARCH, 2011, 71
  • [28] A Phase 2 trial of sipuleucel-T in combination with concurrent or sequential abiraterone acetate (AA) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Small, E.
    Lance, R.
    Gardner, T. A.
    Karsh, L. I.
    Stubbs, A.
    McCoy, C.
    DeVries, T.
    Redfern, C. H.
    Shore, N. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S682 - S683
  • [29] Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto)
    Danila, D. C.
    de Bono, J.
    Ryan, C. J.
    Denmeade, S.
    Smith, M.
    Taplin, M.
    Bubley, G.
    Molina, A.
    Haqq, C.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer
    Ramalingam, Sundhar
    Humeniuk, Michael S.
    Hu, Rachel
    Rasmussen, Julia
    Healy, Patrick
    Wu, Yuan
    Harrison, Michael R.
    Armstrong, Andrew J.
    George, Daniel J.
    Zhang, Tian
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (06) : 418 - 424
12345